Explore professionally built ETF model portfolios. Discover now →

Advertisement
Segment| Data as of 10/26/2026
trending up

Tomorrow's Treatments ETFs

1D perf
0.01%
1D flows
-$3M
Total AuM
$694M
Total ETFs
9

Aggregate data of 9 funds

Performance

-8.0-6.0-4.0-2.00.0%Sep 28Oct 5Oct 12Oct 19Oct 26

Flows

-8 M-6 M-4 M-2 M0 M
1M3MYTD1Y3Y5Y
Perf.-3.12%-5.28%+10.71%+29.76%+104.14%
Flows-$7M+$56M+$215M+$287M+$371M-

Top ETFs in this segment

1D-0.05%1W flows-View
1D-0.03%1W flows-View
1D+0.48%1W flows-View

Just published in Tomorrow's Treatments

View all articles

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Movers in Tomorrow's Treatments

Top
Bottom
Top performers, 1 week1W perf.YTD perf.
SBIO
ALPS Medical Breakthroughs ETF+2.97%+5.07%
CANC
Tema Oncology ETF+2.53%+18.27%
MEDX
Horizon Kinetics Medical ETF+2.27%+10.31%
ASD
Defiance Autism Impact ETF+1.72% 
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF+1.54%+6.07%
Top inflows, 1 week1W flowYTD flows
BBC
Virtus LifeSci Biotech Clinical Trials ETF-+$5M
ASD
Defiance Autism Impact ETF--
HRTS
Tema GLP-1, Obesity & Cardiometabolic ETF--$3M
MEDX
Horizon Kinetics Medical ETF--$3M
BBP
Virtus LifeSci Biotech Products ETF-+$66M

Data period: October 19 - 26, 2026

Performance lists exclude leveraged and inverse ETFs

Recently launched ETFs

Inception

Related indexes by ICE

NYFSGIB
NYSE FactSet Global Genomics and Immuno Biopharma IndexView on ICE
NYFSNBM
NYSE FactSet Global Neuro Biopharma and MedTech IndexView on ICE

Latest news about Thematic Investing: Tomorrow's Treatments

Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities

Small-cap biotech ETFs focus on early-stage companies, offering explosive upside potential but higher risks compared to market-cap weighted competitors.

Biotech etfs

Obesity and Weight-Loss Drugs: A New Thematic ETF Segment?

The ongoing Ozempic and weight-loss drug obsession has investors and ETF issuers turning to new ways of gaining healthcare sector exposure.

Weight-loss-drugs

Two biotech ETFs to watch for the rest of 2022 and beyond

Investors with a high tolerance for risk may seek to gain exposure to the growth potential of the biotech industry. We take a look at two ETFs that have rallied over the last month.

Two biotech ETFs to watch for the rest of 2022 and beyond
Alan Joseph
By Alan Joseph · September 13, 2022
Advertisement
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides

Recent educational content

ETF Investing Trends - First Look

First Look ETF

First Look ETF: Income, International, and Cash Flow ETFs

In this season 6 episode of First Look ETF, Stephanie Stanton ‪@etfguide‬ examines the latest ETF marketplace trends with NYSE and guests.

ETF Guide
By ETF Guide · October 20, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs October 5, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · October 6, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 28, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 29, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 22, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 23, 2026

Browse all educational columns

New Report

ETFs’ Next Act: From Access to Selection

Global ETF Survey 2026